🚀 VC round data is live in beta, check it out!
Geovax Labs Valuation Multiples
Discover revenue and EBITDA valuation multiples for Geovax Labs and similar public comparables like JFL Life Sciences, Modus Therapeutics, Newbury Pharmaceuticals, Acurx Pharmaceuticals and more.
Geovax Labs Overview
About Geovax Labs
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax’s product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company’s key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
Founded
1988
HQ
Employees
17
Website
Sectors
Financials (LTM)
EV
$2M
Geovax Labs Financials
Geovax Labs reported last 12-month revenue of $2M.
In the same LTM period, Geovax Labs generated had net loss of ($24M).
Revenue (LTM)
Geovax Labs P&L
In the most recent fiscal year, Geovax Labs reported revenue of $4M and EBITDA of ($25M).
Geovax Labs expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2M | XXX | $4M | XXX | XXX | XXX |
| EBITDA | — | XXX | ($25M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (629%) | XXX | XXX | XXX |
| EBIT Margin | (1252%) | XXX | (635%) | XXX | XXX | XXX |
| Net Profit | ($24M) | XXX | ($25M) | XXX | XXX | XXX |
| Net Margin | (1247%) | XXX | (632%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Geovax Labs Stock Performance
Geovax Labs has current market cap of $4M, and enterprise value of $2M.
Market Cap Evolution
Geovax Labs' stock price is $1.70.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2M | $4M | 0.0% | XXX | XXX | XXX | $-11.24 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGeovax Labs Valuation Multiples
Geovax Labs trades at 1.2x EV/Revenue multiple, and (0.1x) EV/EBITDA.
EV / Revenue (LTM)
Geovax Labs Financial Valuation Multiples
As of March 30, 2026, Geovax Labs has market cap of $4M and EV of $2M.
Equity research analysts estimate Geovax Labs' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Geovax Labs has a P/E ratio of (0.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4M | XXX | $4M | XXX | XXX | XXX |
| EV (current) | $2M | XXX | $2M | XXX | XXX | XXX |
| EV/Revenue | 1.2x | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.1x) | XXX | XXX | XXX |
| EV/EBIT | (0.1x) | XXX | (0.1x) | XXX | XXX | XXX |
| P/E | (0.2x) | XXX | (0.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Geovax Labs Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Geovax Labs Margins & Growth Rates
Geovax Labs' revenue in the last 12 month declined by (100%).
Geovax Labs' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $1.7M for the same period.
Geovax Labs Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (100%) | XXX | (37%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (629%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (7%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.7M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 269% | XXX | 136% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1033% | XXX | 600% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 736% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Geovax Labs Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| JFL Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Modus Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Newbury Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Acurx Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Strategic Partners | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Geovax Labs M&A Activity
Geovax Labs acquired XXX companies to date.
Last acquisition by Geovax Labs was on XXXXXXXX, XXXXX. Geovax Labs acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Geovax Labs
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGeovax Labs Investment Activity
Geovax Labs invested in XXX companies to date.
Geovax Labs made its latest investment on XXXXXXXX, XXXXX. Geovax Labs invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Geovax Labs
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Geovax Labs
| When was Geovax Labs founded? | Geovax Labs was founded in 1988. |
| Where is Geovax Labs headquartered? | Geovax Labs is headquartered in United States. |
| How many employees does Geovax Labs have? | As of today, Geovax Labs has over 17 employees. |
| Who is the CEO of Geovax Labs? | Geovax Labs' CEO is David A. Dodd. |
| Is Geovax Labs publicly listed? | Yes, Geovax Labs is a public company listed on Nasdaq. |
| What is the stock symbol of Geovax Labs? | Geovax Labs trades under GOVX ticker. |
| When did Geovax Labs go public? | Geovax Labs went public in 1995. |
| Who are competitors of Geovax Labs? | Geovax Labs main competitors are JFL Life Sciences, Modus Therapeutics, Newbury Pharmaceuticals, Acurx Pharmaceuticals. |
| What is the current market cap of Geovax Labs? | Geovax Labs' current market cap is $4M. |
| What is the current revenue of Geovax Labs? | Geovax Labs' last 12 months revenue is $2M. |
| What is the current revenue growth of Geovax Labs? | Geovax Labs revenue growth (NTM/LTM) is (100%). |
| What is the current EV/Revenue multiple of Geovax Labs? | Current revenue multiple of Geovax Labs is 1.2x. |
| Is Geovax Labs profitable? | No, Geovax Labs is not profitable. |
| What is the current net income of Geovax Labs? | Geovax Labs' last 12 months net income is ($24M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.